Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030140 | 0.88 | KMT2A (0.40) | KDM4EHTR1AALDH1A1LMNAKMT2A | |
| SCHEMBL980703 | 0.88 | HTR1A (0.40) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL1030142 | 0.88 | KMT2A (0.40) | KDM4EHTR1AALDH1A1LMNAKMT2A | |
| SCHEMBL980704 | 0.88 | HTR1A (0.40) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL13624814 | 0.84 | RAB9A (0.36) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL10126869 | 0.84 | RAB9A (0.36) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL12018913 | 0.84 | RAB9A (0.36) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL12018912 | 0.83 | OPRD1 (0.37) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL10126868 | 0.83 | OPRD1 (0.37) | TSHRCYP3A4CYP1A2CYP2D6MAPK1 | |
| SCHEMBL1022236 | 0.82 | CYP2D6 (0.42) | KDM4ETSHRCYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2448935-B1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2448946-B1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293753-B2 | Substituted 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| EP-2448935-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | NOVARTIS AG (CH) | 2011-01-06 | — | — | US | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000905-A1 | SUBSTITUTED 2-CARBOXAMIDE CYCLOAMINO UREAS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | PIK3C3, PRKACA, UACA | KDM4E 1283/4885TSHR 3213/4885CYP3A4 2936/4885 |
| US-20110003818-A1 | Substituted 2-Carboxamide Cycloamino Ureas | UCK2, ULK3, ULK2 | KDM4E 1270/4885TSHR 2608/4885CYP3A4 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.